Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young Sells 10,000 Shares

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Jonathan Young sold 10,000 shares of Akero Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $28.18, for a total value of $281,800.00. Following the completion of the sale, the chief operating officer now directly owns 226,286 shares in the company, valued at approximately $6,376,739.48. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Jonathan Young also recently made the following trade(s):

• On Tuesday, September 10th, Jonathan Young sold 568 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total value of $14,870.24.
• On Thursday, August 1st, Jonathan Young sold 5,000 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.75, for a total value of $133,750.00.

Akero Therapeutics Stock Performance

Shares of NASDAQ AKRO opened at $28.24 on Friday. The company has a current ratio of 24.89, a quick ratio of 24.89 and a debt-to-equity ratio of 0.04. Akero Therapeutics, Inc. has a 12 month low of $11.25 and a 12 month high of $50.42. The stock has a 50 day moving average of $26.53 and a 200-day moving average of $23.92. The company has a market capitalization of $1.95 billion, a P/E ratio of -8.83 and a beta of -0.26.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, August 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.09. As a group, equities research analysts predict that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Cantor Fitzgerald reissued an “overweight” rating on shares of Akero Therapeutics in a research report on Thursday, June 20th. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Akero Therapeutics in a research report on Tuesday, September 17th. Finally, Wolfe Research started coverage on Akero Therapeutics in a research report on Tuesday, June 11th. They set an “outperform” rating on the stock. One research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Akero Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $41.13.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Wellington Management Group LLP boosted its stake in shares of Akero Therapeutics by 247.7% during the 4th quarter. Wellington Management Group LLP now owns 2,881,989 shares of the company’s stock worth $67,294,000 after acquiring an additional 2,053,028 shares during the period. Vanguard Group Inc. boosted its stake in shares of Akero Therapeutics by 19.0% during the 1st quarter. Vanguard Group Inc. now owns 3,669,923 shares of the company’s stock worth $92,702,000 after acquiring an additional 584,875 shares during the period. Perceptive Advisors LLC boosted its stake in Akero Therapeutics by 8.1% in the 2nd quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock valued at $35,188,000 after purchasing an additional 112,426 shares during the period. Capstone Investment Advisors LLC bought a new stake in Akero Therapeutics in the 1st quarter valued at $2,205,000. Finally, Seven Eight Capital LP bought a new stake in Akero Therapeutics in the 4th quarter valued at $1,459,000.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.